...
首页> 外文期刊>Clinical and experimental allergy : >Acquisition, remission, and persistence of eczema, asthma, and rhinitis in children
【24h】

Acquisition, remission, and persistence of eczema, asthma, and rhinitis in children

机译:湿疹,哮喘和鼻炎的收购,缓解和持续存在儿童

获取原文
获取原文并翻译 | 示例

摘要

Summary Background Allergic sensitization is associated with eczema, asthma, and rhinitis. However, it is unknown whether and how allergic sensitization is associated over time with acquisition, remission, and persistence of these diseases and their comorbidity. Objective To gain a better understanding of factors including allergic sensitization transitions that influence the temporal pattern of asthma, eczema, and rhinitis and their comorbidity during childhood. Methods In the Isle of Wight birth cohort, information on allergic sensitization to common allergens was collected at ages 4, 10, and 18 years along with asthma, rhinitis, and eczema status determined by clinical diagnosis. Logistic regressions were used to estimate subsequent and concurrent odds ratios of diseases transition with allergic sensitization transition status as the main independent variable. Two transition periods were considered, 4 to 10 years of age and 10 to 18 years of age. Results The odds of new diagnosis of allergic disease (no‐yes) was increased among subjects with acquired or persistent allergic sensitization to common allergens compared to subjects with no sensitization (acquisition of sensitization odds ratio [OR]=3.22, P .0001; persistence of sensitization, OR=6.33, P .0001). The odds of remission of allergic diseases (yes‐no) was lower among subjects with acquired or sustained allergic sensitization (acquisition, OR=0.18, P = .0001; persistence, OR=0.085, P .0001), compared to subjects not sensitized. Subjects with acquired or persistent allergic sensitization were also had higher odds for persistence of disease (yes‐yes) than subjects not sensitized (acquisition, OR=5.49, P = .0001; persistence, OR=11.79, P .0001). Conclusion Transition of allergic sensitizations to common allergens is a prognostic factor for subsequent or concurrent transition of eczema, asthma, and rhinitis. Prevention or reduction in allergic sensitization has a potential to lead to remission of these conditions.
机译:发明内容背景敏感性敏化与湿疹,哮喘和鼻炎有关。然而,它未知是否以及如何随着这些疾病及其合并症的收购,缓解和持续存在而随着时间的推移而相关。目的是更好地理解因素,包括影响哮喘,湿疹和鼻炎的时间模式的过敏性敏感转变及其在儿童期间的合并症。方法在智能出生队列的岛,在4,10岁及18岁及18岁及18岁及其临床诊断确定的哮喘,鼻炎和湿疹状态下收集有关常见过敏剂的过敏反应的信息。逻辑回归用于估计随后的疾病转型和同时的疾病转型,其具有过敏性敏感转换状态作为主要的独立变量。考虑了两个过渡期,4至10岁,10至18岁。结果与没有敏化的受试者的受试者获得或持续过敏致敏对常见过敏症的受试者(NO-YER)新诊断的几率(NO-YER)增加了常见过敏原的受试者(获取致敏机会比率[或] = 3.22,P& .0001 ;敏感性持续性,或= 6.33,p& .0001)。与受试者相比,受试者或持续过敏性致敏的受试者中过敏疾病缓解的几率(是-NO)(yes-no)的几率降低了受试者(收购,或= 0.18,p = .0001)不敏感。具有患有或持续过敏性敏感性的受试者也具有比未致敏的受试者持续存在的疾病(是 - 是)的几率较高(是 - 是)(获取,或= 5.49,p = .0001;持久性,或= 11.79,P& .0001)。结论过敏敏化素对共同过敏原的转变是后续或同时转型的湿疹,哮喘和鼻炎的预后因素。预防或降低过敏性敏感性有可能导致缓解这些条件。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号